Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | CCR3 | P51677 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10148279 | 0.86 | USP2 (0.60) | USP2HRH1CCR3KCNH2KDM4E | |
| SCHEMBL382303 | 0.85 | MAPT (0.49) | CHRM4ALDH1A1MAPTKMT2A | |
| SCHEMBL462291 | 0.84 | HRH3 (0.47) | USP2KDM4EHDAC3HDAC8CHRM4 | |
| SCHEMBL382501 | 0.83 | CHRM2 (0.50) | CHRM4MAPT | |
| SCHEMBL7911517 | 0.82 | USP2 (0.65) | USP2HRH1CCR3KCNH2KDM4E | |
| SCHEMBL1663774 | 0.80 | USP2 (0.62) | USP2HRH1CCR3KCNH2KDM4E | |
| SCHEMBL23051536 | 0.79 | USP2 (0.69) | USP2HRH1CCR3KCNH2KDM4E | |
| SCHEMBL28718607 | 0.77 | USP2 (0.58) | USP2HRH1CCR3KCNH2KDM4E | |
| SCHEMBL1663654 | 0.77 | USP2 (0.66) | USP2HRH1CCR3KCNH2KDM4E | |
| SCHEMBL460572 | 0.77 | PTGER2 (0.46) | USP2KDM4EHDAC3HDAC8CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476253-B2 | Amide derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-02 | — | — | US | disclosed |
| US-20120071467-A1 | AMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| EP-2409977-A1 | AMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2012-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071467-A1 | AMIDE DERIVATIVE | CHRM3, CHRM2, TACR2 | USP2 2694/4885HRH1 182/4885CCR3 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.